RXRX Q1 2022 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+112.0% YoY

Gross Profit

-$3M-47.2% margin

Operating Income

-$56M-1056.4% margin

Net Income

-$56M-1056.4% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+112.0%

Cash Flow

Operating Cash Flow

$77M

Free Cash Flow

$73M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$734M

Total Liabilities

$241M

Stockholders' Equity

$494M

Cash & Equivalents

$508M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+112.0%
Gross Profit	-$3M	$3M	-200.0%
Operating Income	-$56M	-$30M	-83.6%
Net Income	-$56M	-$31M	-82.2%

Revenue Segments

License and Service

$5M99%

Grant

$34,0001%